Related Experiment Video

Updated: Jul 6, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

Muhammad Tufail1, Jia-Ju Hu1, Jie Liang1

  • 1Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China.

Journal of Translational Medicine
|January 3, 2024
PubMed

Insights

Targeting the phosphatidylinositol 3-kinase (PI3K) pathway offers promise for breast cancer (BC) treatment. Understanding PI3K pathway roles aids in developing predictive biomarkers and personalized therapies for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer (BC) presents diverse molecular subtypes with varied treatment responses.
  • The phosphatidylinositol 3-kinase (PI3K) pathway is integral to BC development, progression, and therapeutic resistance.

Purpose of the Study:

  • To review the role of the PI3K pathway in predictive, preventive, and personalized medicine for breast cancer.
  • To highlight PI3K pathway implications for biomarker identification and tailored treatment strategies.

Main Methods:

  • Literature review focusing on PI3K pathway research in breast cancer.
  • Analysis of studies on PIK3CA mutations, molecular profiling, and therapeutic targeting.
  • Exploration of preventive strategies and combination therapies.

Main Results:

  • PIK3CA mutations serve as predictive biomarkers for BC treatment.
  • Molecular profiling guides personalized therapy selection based on tumor characteristics.
  • Targeting the PI3K pathway shows potential for prevention and customized treatment.

Conclusions:

  • The PI3K pathway is a critical target for advancing predictive, preventive, and personalized breast cancer medicine.
  • Further research and clinical validation are essential to translate PI3K-targeted strategies into clinical practice.
  • Overcoming resistance and exploring combination therapies are key for maximizing therapeutic benefits.
Keywords:
Breast cancerPI3K pathwayPersonalized medicinePredictive medicinePreventive medicine

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.1K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.6K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K